Akhtar Samad Net Worth

What's Akhtar Samad's mailing address?

Akhtar's mailing address filed with the SEC is 2 Gansevoort St 9TH FLOOR, New York, NY 10014, USA.

Insiders trading at Avenue Therapeutics Inc

Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss et Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.

What does Avenue Therapeutics Inc do?

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.

Avenue Therapeutics Inc executives and stock owners

Avenue Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lucy Lu,
  President, Chief Executive Officer, Director
• Dr. Xiaoqin Lu M.D.,
  Pres, CEO & Director
• Joseph Vazzano,
  Chief Financial Officer, Principal Financial Officer and Corporate Secretary
• Joseph Walter Vazzano,
  CFO, Principal Financial Officer & Company Sec.
• Neil Herskowitz,
  Independent Director
• Jay Kranzler,
  Independent Director
• Thomas Moore,
  Independent Director
• Dr. Lindsay Allan Rosenwald,
  Exec. Chairman
• Garrett Ingram,
  Director
• Jaideep Gogtay,
  Director
• Lindsay Rosenwald,
  Executive Chairman of the Board
• Dr. Scott A. Reines M.D., Ph.D.,
  Interim Chief Medical Officer
• Jeffrey Paley,
  Director
• Akhtar Samad,
  Director
• Scott Reines,
  Interim Chief Medical Officer
• Michael S Weiss,
  Director
• Curtis Gale Oltmans,
  Director
• Pharmaceuticals, Inc. Inva Gen,
  10% owner
• Robert L Davidow,
  10% owner
• Biotech, Inc. Fortress,
  10% owner
• David Jin,
  Interim PFO and COO
• Faith L. Charles,
  Director